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ABSTRACT
We had previously reported that trivalent arsenic (As3+), a well-known 
environmental carcinogen, induces phosphorylation of several putative Akt substrates. 
In the present report, we characterized one of these substrates by immunoprecipitation 
and proteomics analysis. The results indicate that a cytoskeleton remodeling 
protein, filamin A, with a molecular weight around 280 kDa, is phosphorylated by 
Akt in HEK-293 cells treated with As3+, which was also confirmed in human bronchial 
epithelial cell line, BEAS-2B cells. Additional biochemical and biological studies 
revealed that serine 2152 (S2152) of filamin A is phosphorylated by activated Akt 
in the cells treated with As3+. To further confirm the importance of Akt-dependent 
filamin A S2152 phosphorylation in As3+-induced cell migration, we over-expressed 
either wild type filamin A or the mutated filamin A in which the S2152 was substituted 
with alanine (S2152A). The capability of cell migration was reduced significantly 
in the cells expressing the mutated filamin A (S2152A). Clinically, we found that 
increased expression of filamin A predicts poorer overall survival of the lung cancer 
patients with adenocarcinoma. Thus, these data suggest that Akt dependent filamin 
A phosphorylation is one of the key events in mediating As3+-induced carcinogenesis. 
Antagonizing Akt signaling can ameliorate As3+-induced filamin A phosphorylation and 
cell migration, which may serve as a molecular targeting strategy for malignancies 
associated with environmental As3+ exposure.
INTRODUCTION
Arsenic is a well-established carcinogen involved 
in the development of several types of cancers, e.g., 
cancers of the lung, skin, bladder, and liver [1]. Based 
on their chemical characteristics, the arsenic-containing 
compounds can be classified into organic and inorganic 
forms. It is believed that the inorganic form, especially, 
the trivalent arsenic (As3+), is much more toxic and 
carcinogenic. The International Agency for Research 
on Cancer (IARC) has classified arsenic as group 
I carcinogen [2]. As a naturally deposited metalloid, 
arsenic is widely distributed throughout the Earth’s crust. 
Some common environmental conditions, such as aquifers 
under strongly reducing conditions in wet and flat regions 
and aerobic alkaline conditions in closed basins in arid and 
semiarid regions, can promote the release of arsenic from 
sediments to the dissolved forms in ground or drinking 
water [3]. Accumulating evidence had indicated an 
increased incident rate of lung cancer among populations 
with moderate to high level of As3+ exposure [4]. 
Worldwide, there is an estimation of 160 million people 
who are living in regions with elevated levels of arsenic 
in drinking water, including areas in the USA, China, 
Taiwan, Mexico, Mongolia, Argentina, India, Chile, and 
Bangladesh [5]. Thus, understanding how arsenic exposure 
is linked to human cancers is urgently needed.
Several lines of evidence suggest that arsenic, 
especially As3+, is capable of inducing malignant 
transformation of the normal cells by mechanisms 
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of oxidative stress, DNA damage, interference of the 
DNA repairing processes, and disruption of the immune 
surveillance function [6]. In human bronchial epithelial 
cells or lung cancer cells, we had shown that As3+ is able 
to activate protein kinase Akt through either inducing 
miR-190 or initiating the signaling cascade from JNK 
to STAT3 that contributes to Akt-dependent EZH2 
phosphorylation, cell transformation and/or migration 
[7–10]. Akt has long been viewed as a master regulator 
of epithelial-mesenchymal transition (EMT), cancer cell 
migration, invasion, and metastasis [11, 12]. Akt can 
directly phosphorylate ACAP1, Pak1, POSH, Girdin, and 
Twist that contain R-X-R-X-X-S/T or R-X-X-S/T Akt 
phosphorylation motif, followed by integrin recycling, 
actin cytoskeleton remodeling and EMT [13, 14].
Metastasis, in which cancer cells migrate to 
the secondary site(s) from their original tumor site, 
occurred in almost all cancers that progressed to 
later stages [15, 16]. In addition to the capabilities of 
cancer cells in proliferation and apoptotic responses 
for colonization at the secondary site, the key event of 
metastasis is migration of the cancer cells [17]. A number 
of cytoskeleton remodeling proteins are involved in 
cancer cell detachment, polarization and mobilization. 
In non-muscle cells, filamin A was the first discovered 
actin-filament crosslinking protein that interacts with 
integrins and several other cytoskeleton remodeling 
proteins [18–20]. Intriguingly, this protein has also 
been confirmed as a substrate for some protein kinases, 
including FAK, Lck [21], PAK1 [22], MAPK [23], and 
Akt [24], indicating that phosphorylation of filamin A is 
an essential step in initiating filamin A interaction with 
the cytoskeleton remodeling proteins or integrins for cell 
migration [25].
In this report, we provide evidence suggesting 
that As3+-induced cell migration is achieved through ROS-
dependent activation of Akt that phosphorylates filamin A 
at serine 2152 in human bronchial epithelial cell line, 
BEAS-2B. Pharmacological inhibition of Akt or gene 
silencing of filamin A attenuated migration of the cells 
treated with As3+. These data, thus, may provide a new 
insight into the mechanism of tumorigenesis related to 
environmental As3+ exposure.
RESULTS
Identification of filamin A as a substrate of As3+-
induced Akt
We had previously demonstrated several Akt 
phosphorylation substrates in immunoprecipitation (IP) 
analyses of the BEAS-2B cells treated with As3+ [10]. To 
test whether these Akt substrates are also presented in 
other types of cells in response to As3+, we performed IP 
analysis using cell lysates from HEK-293 cells cultured 
in the absence or presence of 20 μM As3+ for 2 h and 
an antibody specifically recognizing the phosphorylated 
Akt phosphorylation motif, R-X-R-X-X-S/T. As depicted 
in Fig. 1A, a band with an estimated molecular weight 
about 280 kDa was constitutively detected in HEK-293 
cells (pointed with a black block arrow). Treatment 
of the cells with As3+ enhanced the density of this 
band considerably. Pre-incubation of the cells with an 
antioxidant, NAC that scavenges reactive oxygen species 
(ROS), diminished this band completely, suggesting 
that the occurrence of this band is ROS-dependent. To 
determine the nature of this protein band that can be 
recognized by an anti-Akt phosphorylation substrate 
antibody, we retrieved this band from Western blotting 
membrane and subjected it to proteomics analysis 
through tryptic digestion and peptide identification 
using orbitrap Fusion mass spectrometry as described 
under Materials and Methods. The peptides identified 
from this analysis suggested a possible presence of 
11 proteins in this protein band as detected in IP, 
among which only two proteins, filamin A and inositol 
1,4,5-trisphosphate receptor type 3 (ITPR3), are within 
the range of molecular weight between 200 and 300 kDa 
where the original band was positioned. The filamin A 
was represented by 10 peptides, whereas ITPR3 was 
represented by only 4 peptides. Thus, we concluded that 
the most abundant protein in this IP band is filamin A 
based on the assumption that the number of peptides 
identified in mass spectrometry is generally proportional 
to its abundance or concentration in the sample.
Protein-protein interaction between Akt 
and filamin A
To further confirm filamin A as an Akt substrate, 
we next determined whether there is a direct interaction 
between protein kinase Akt and filamin A in BEAS-2B 
cells treated with As3+ through immunoprecipitation. 
Again, the anti-Akt substrate antibody was able to 
pull down filamin A in the cells treated with As3+ 
(Fig. 1C, top two panels). Using antibodies against 
either the total Akt or phospho-Akt (pAkt), we showed 
that both activated and total Akt were able to interact 
with filamin A that was phosphorylated at serine 2152 
(S2152), and this interaction occurred only in the 
cells treated with As3+ but not the cells without As3+ 
treatment (Fig. 1C). To exclude the possibility of non-
specific protein-protein interaction during IP, we also 
used control IgG in our immunoprecipitation assay. It 
is clear that only the anti-pAkt antibody, but not IgG, 
can pull down the phosphorylated filamin A (Fig. 1D). 
Therefore, these data provided substantial evidence 
indicating that filamin A is an endogenous Akt substrate 
that can be phosphorylated by Akt through direct 
interaction.
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ROS mediate As3+-induced Akt activation that 
phosphorylates filamin A
To extend above observations, we pretreated the 
cells with Wortmannin, an inhibitor that is relatively 
specific for the upstream kinase, PI3K that phosphorylates 
and activates Akt, in the BEAS-2B cells. A roughly 
dose-dependent inhibition of the As3+-induced filamin 
A phosphorylation was observed in the cells pretreated 
with 10 or 20 μM Wortmannin that diminished Akt 
activation completely (Fig. 2A). This inhibitor had no 
detectable effect on the protein levels of non-phospho-
filamin A, total Akt or β-actin (Fig. 2A). The requirement 
of activated Akt kinase in As3+-induced filamin A 
phosphorylation was further validated by silencing 
Akt using siRNA that specifically down-regulates Akt 
expression. As indicated in Fig. 2B, the control siRNA 
with scramble sequence (siCtrl) has no inhibitory effect, 
neither on the level of phospho-filamin A (pFilamin AS2152) 
nor the total Akt. Silencing Akt using Akt specific siRNA 
(siAkt) not only reduced the levels of total Akt and the 
activated pAkt, but also attenuated phosphorylation of 
filamin A in the cells treated with As3+ (Fig. 2B). Taken 
together, these data clearly suggest that the As3+-induced 
Akt activation, as determined by the phosphorylation on 
serine 473 (S473), is essential for the phosphorylation of 
filamin A at S2152.
We had previously demonstrated that As3+ induces 
excessive generation of ROS that contribute to Akt 
activation [10] and the subsequent transformation of the 
cells [26]. To address the role of ROS in As3+-induced 
filamin A phosphorylation, we first treated the cells with 
Figure 1: Identifying filamin A as an Akt substrate. A. HEK-293 cells were treated with 20 μM As3+ in the presence or absence of 
10 mM N-acetyl L Cysteine for 2 h. Cell lysates were prepared using non-denature buffer and subjected to immunoprecipitation (IP) using 
anti-Akt substrate antibody. Block arrow denotes protein band on the PVDF membrane that was retrieved for mass spectrometry analysis. 
B. Mass Spectrometry result shows the peptide profiling that overlaps sequence of filamin A. Top two panels are representative spectrums of 
the peptides from filamin A. C. BEAS-2B cell were treated as in (A), and subjected to IP using the indicated antibodies followed by Western 
blotting (WB). D. BEAS-2B cells were treated with 20 μM As3+ for 2 h, followed by IP using IgG or pAkt antibody as indicated and then 
WB using phospho-Filamin A (pFilamin A) or pAkt antibody.
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As3+ in the absence or presence of 20 mM NAC, a widely 
used ROS scavenger. As expected, NAC prevented As3+-
induced Akt activation and filamin A phosphorylation 
(Fig. 2C). The role of ROS in As3+-induced filamin A 
phosphorylation was additionally confirmed by treatment 
of the BEAS-2B cells with 200 mM H2O2 for 5 to 60 min. 
Indeed, H2O2 is able to induce Akt activation and filamin A 
phosphorylation in a time dependent manner. The 
activation of Akt and phosphorylation of filamin A can be 
detected as early as 5 min after the cells treated with H2O2. 
At 30 min, the filamin A phosphorylation reached plateau 
(Fig. 2D).
As3+ induces cell migration through Akt 
activation
Activation of Akt has been linked to a number of 
cellular processes, including cell growth, anti-apoptosis, 
transformation, migration, invasion, and metastasis 
of the cancer cells [27]. Accordingly, it is plausible to 
hypothesize that the activation of Akt by As3+ can be 
involved in cell migration. To test this, we first treated 
BEAS-2B cells with As3+ and then measured cell migration 
capability using Matrigel-based Migration Chambers. 
As3+ treatment promoted cell migration significantly 
(Figs. 3A and 3C). Silencing Akt using Akt specific siRNA 
reduced the number of the migrated cells in response to 
As3+. As3+-induced cell migration was not affected by the 
control siRNA (siCtrl, Figs. 3B and 3C).
Filamin A phosphorylation is required for As3+-
induced cell migration
To answer whether filamin A phosphorylation served 
as a downstream signal for As3+-induced Akt activation 
that facilitates cell migration, we next silenced filamin 
A by transfection of the cells with filamin A specific 
siRNA (siFlna) followed by measuring the cell migration. 
Filamin A specific siRNA, siFlna, reduced the levels of 
both filamin A and the S2152-phosphorylated filamin A 
(pFilamin AS2152) notably (Fig. 4A). The control siRNA, 
siCtrl, exhibited no significant effects on these proteins, 
neither pFilamin A, nor total Filamin A. In cell migration 
assays, again, As3+ increased the number of migrated cells 
significantly (Figs. 4B and 4C). No inhibition of the As3+-
induced cell migration was detected in the cells transfected 
with the control siRNA (siCtrl). In contrast, a strong 
inhibition of cell migration induced by As3+ was observed 
Figure 2: As3+-induced Akt activation and filamin A phosphorylation are ROS dependent. A. BEAS-2B cells were treated 
with 20 μM As3+ for 2 h with or without pretreatment with 20 μM wortmannin. The protein levels of phospho-filamin AS2152, filamin A, 
pAktS473, Akt, and β-actin were determined by WB. B. BEAS-2B cells were transfected with 50 nM Ctrl siRNA or Akt siRNA with or 
without an additional treatment of As3+ for 2 h. WB was then performed as in (A). C. BEAS-2B cells were treated with the indicated 
concentrations of As3+ and/or NAC. WB was then performed as in (A). D. Time-dependent induction of filamin A phosphorylation by H2O2 
in BEAS-2B cells.
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Figure 3: As3+-induced cell migration is Akt dependent. A. Migration assay shows elevated motility of the BEAS-2B cells 
treated with 20 μM As3+ for 24 h. B. Silencing Akt by siRNA reduces As3+-induced cell migration. BEAS-2B cells were transfected with 
50 nM control siRNA (siCtrl) or Akt siRNA (siAkt). C. Semi-quantification of the migrated cells as shown in (B). Data are expressed as 
mean ± SD, n = 12, ***p < 0.001, **p < 0.01.
Figure 4: Silencing filamin A prevented As3+-induced cell migration. A. BEAS-2B cells were transfected with 50 nM control 
siRNA (siCtrl) or filamin A siRNA (siFlna) with or without treatment by 4 μM As3+ for 24 h. B. Representative images of the migration 
assays. BEAS-2B cells were treated as in (A). C. Semi-quantification of the migrated cells as shown in (B). Data are expressed as mean ± SD, 
n = 12, *p < 0.05.
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in the cells transfected with siFlna that specifically 
silences filamin A (Figs. 4B and 4C). These observations, 
thus, not only reinforced the notion that filamin A might 
be an important regulator for cell migration [24, 28], but 
also provided strong evidence indicating that filamin A is a 
downstream effecter to bridge As3+-induced Akt activation 
and migration.
Disruption of filamin A phosphorylation impairs 
cell migration
Several lines of evidence had indicated the essential 
role of filamin A for mammalian cell locomotion. 
However, how this function of filamin A is regulated 
remains to be fully understood. Since As3+ induces 
direct interaction between Akt and filamin A (Fig. 1), 
which leads to S2152 phosphorylation of filamin A 
(Figs. 2A and 2B), it is very likely that the migration 
regulation by filamin A depends on the phosphorylation 
of filamin A at S2152. To explore this possibility, we 
transfected BEAS-2B cells with an expression vector 
containing myc-tagged full-length filamin A (myc-Flna, 
wild-type) or myc-tagged filamin A in which the serine 
2152 was mutated to alanine (S2152A). The substitution 
of S2152 with alanine abrogated the phosphorylation of 
filamin A as revealed in an IP experiment using anti-myc 
tag antibody (Fig. 5A). Resembling the cells treated with 
As3+, cells with an overexpression of the full-length wild-
type filamin A exhibited an enhanced migration capability 
(Figs. 5B and 5C). On the other hand, the migratory ability 
of the cells expressing the mutated filamin A, S2152A, 
was much reduced relative to the cells expressing wild-
type filamin A (Figs. 5B and 5C). Thus, phosphorylation of 
filamin A at S2152 by As3+-activated Akt is a prerequisite 
step for cell migration.
The expression level of filamin A predicts 
prognostic outcomes of the lung cancer patients
To establish clinical relevance of the above findings, 
we investigated correlation between the expression level 
of filamin A and the survival times of the lung cancer 
patients by using an online database of Kaplan-Meier 
Plotter that contains gene profiling information from 
2,437 human lung cancer samples [29]. Three overlapping 
sets of probes are included in this database to mostly detect 
the open-reading-frame (ORF) of the filamin A mRNA. 
In initial analysis, we found that the expression level of 
Figure 5: Phosphorylation of Filamin A on Ser2152 is required for As3+-induced cell migration. A. BEAS-2B cells were 
transfected with 2 μg myc-filamin A (wild type, myc-Flna) plasmid or myc-filamin A S2152A (2152A) plasmid, followed by IP using 
anti-myc tag antibody and WB using the indicated antibodies. B. Representative images of cell migration assay of the BEAS-2B cells that 
were transfected with 2 μg myc-filamin A (myc-Flna) plasmid or myc-filamin A S2152A (2152A) plasmid. C. Semi-quantification of the 
migrated cells as shown in (A & B). Data are expressed as mean ± SD, n = 12, *p < 0.05.
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filamin A did not distinguish poorer or better survival 
times of the patients when all types of lung cancers 
were included. After stratifying the lung cancer patients 
based on their status of cigarette smoking, e.g., never-
smoked or smoked, it was found that higher expression 
level of filamin A predicts poorer overall survival of the 
patients who were never-smoked (Fig. 6A). In contrast, 
higher expression of filamin A appeared to be no effect 
on the overall survival among those patients who were 
current or former smokers (Fig. 6B). Since it had been 
well-documented that cigarette smoking contributes to 
different histological subtypes of the lung cancer [30], we 
believed that the opposite predictive power of filamin A 
expression between smoked and never-smoked might be a 
reflection of the different histological subtypes of the lung 
cancers. Therefore, we next compared the overall survival 
of the patients with either adenocarcinoma or squamous 
cell carcinoma based on the higher or lower expression 
level of filamin A. It is true that higher level of filamin 
A predicts a significant poorer survival of the patients 
with adenocarcinoma (Fig. 6C), but not the squamous cell 
carcinoma (Fig. 6D).
DISCUSSION
The molecular or biochemical basis of As3+-
induced cell transformation, carcinogenesis and 
tumorigenesis is not well defined. In the present study, 
we unraveled a signaling cascade for As3+-induced 
cell migration. In both human HEK-293 cells and 
bronchial epithelial cell line BEAS-2B cells, our data 
suggest that As3+ induces activation of Akt that interacts 
with and phosphorylates filamin A, an actin-binding 
protein responsible for crosslinking actin filaments into 
the membrane glycoproteins and integrins [18–20]. 
Activation of Akt by As3+ appears to be ROS dependent, 
based on the fact that NAC, a widely used antioxidant, 
blocked As3+-induced Akt activation and the subsequent 
filamin A phosphorylation. This notion was additionally 
supported by the observation that H2O2, the most common 
intracellular oxidative molecule, can activate Akt, leading 
to the phosphorylation of filamin A. Silencing either Akt or 
filamin A using specific siRNAs impaired cell migration in 
response to As3+. Furthermore, our data also demonstrated 
that Akt-dependent phosphorylation on S2152 of filamin A 
is involved in cell migration, since overexpression of the 
mutated filamin A, in which S2152 was replaced with 
alanine, reduced the capability of cell migration. Taken 
together, these results provide the first evidence indicating 
that As3+ induces cell migration through signaling pathway 
from ROS to Akt that phosphorylates filamin A.
The association between environmental As3+ 
exposure and carcinogenesis had been well-established. 
Majority of studies so far addressed the potential effects 
of As3+ on the initiation of cell transformation and/or 
carcinogenesis, such as DNA damage responses, inhibition 
Figure 6: The expression level of filamin A is a prognostic factor for the lung cancer patients. A & B. High level of filamin 
A predicts poorer overall survival of the lung cancer patients who were never-smoked, but not those who were smoked. C & D. High level 
of filamin A predicts poorer overall survival of the patients with adenocarcinoma, but not those patients with squamous cell carcinoma. 
Statistical significance was determined by logrank p-values as indicated. The panels depict Kaplan-Meier survival probability with the 
probe ID 200859_x_at. Similar data were obtained when probe ID 214752_x_at and 213746_s_at were used.
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of the DNA repairing machinery, impairment of the 
immune surveillance system, alteration of the epigenetic 
modifications on the genome, and activation of a wide 
range of signaling pathways that linked to transcription 
factors and gene expression [4]. Very limited information 
is available, however, on whether As3+ is also capable of 
regulating the key processes of tumorigenesis, including 
tumor cell motility, invasion and metastasis. Several 
reports as well as our previous studies had suggested that 
As3+ is a potent activator for the multi-functional protein 
kinase Akt that had been linked to tumor angiogenesis, 
tumor cell metastasis and metabolism [7–10, 31, 32]. 
Accumulating evidence has suggested that Akt can not 
only provide the cells with growth advantages by eliciting 
proliferative or anti-apoptotic signals but also engage with 
motility of the cells through regulating actin tethering and 
stress fiber assembly [33]. Thus, it is very likely that in 
addition to the earlier events of carcinogenesis, As3+ can 
also participate in the tumorigenic process through Akt 
activation.
As revealed by IP using anti-Akt phospho-substrate 
antibody followed by proteomic analysis of the proteins 
in the immunocomplexes, we provide the first evidence 
demonstrating a direct interaction between Akt and 
filamin A in cellular response to As3+. This interaction 
results in phosphorylation of filamin A at S2152. Akt-
dependent phosphorylation of filamin A at S2152 has 
been previously determined in prostate cancer cells and 
the IGF-1-treated MCF-7 cells [24, 34]. It is believed that 
this phosphorylation can prevent cleavage of filamin A 
and enhance its association with caveolin-1 [24, 34]. 
Few studies also implied that S2152 phosphorylation of 
filamin A by other protein kinases, such as PAK1 or RSK, 
might be involved in the formation of membrane ruffling 
and lamellipodia extension, the necessary steps for cell 
migration and tumor cell metastasis [35, 36]. Furthermore, 
studies using molecular dynamics simulations unraveled 
that phosphorylation of filamin A at S2152 can facilitate 
integrin binding of filamin A by conformational changes 
that open the primary binding site of integrin on the Ig 
repeat 21 of filamin A [25]. Thus, an Akt-dependent 
phosphorylation of filamin A induced by As3+ may 
enhance the capability of integrin binding of filamin A, 
and consequently, foster migration of the cells.
The observation that increased filamin A 
expression predicts poorer overall survival of the 
never-smoked patients and adenocarcinoma (Fig. 6) 
provided compensatory supporting evidence suggesting 
involvement of filamin A in lung malignancy. More 
importantly, it is highly possible that this observation 
serves as a strong indication that this protein may 
impact the aggressiveness of the specific histological 
subtypes of the human lung cancer. Many earlier 
studies had revealed that adenocarcinoma most likely 
occurred in the younger, never-smoked and females with 
a much aggressive disease progression [37, 38]. It is 
also noteworthy that there is an increased proportion of 
adenocarcinoma among U.S. copper smelter workers who 
were exposed to As3+ through inhalation [39]. Due to the 
higher frequency of mutation on the gene loci encoding 
LKB1, an extensively studied tumor suppressor that 
suppresses metastasis of the tumor cells, adenocarcinoma 
appears to be more metastatic compared with squamous 
cell carcinoma or large cell carcinoma [40, 41]. As 
tumor cell metastasis is one of the major biological 
factors contributing to the aggressiveness of tumors, it is 
plausible, thus, to assume that increased level of filamin A 
can enhance the migration and metastasis potentials of the 
cancer cells, especially for the adenocarcinoma. Although 
phosphorylation status of filamin A on patient prognostic 
outcomes was not evaluated due to the unavailability of 
such data, a proportional increase of the phosphorylated 
filamin A can be envisioned among those patients 
with a higher level of overall expression of filamin A. 
Accordingly, the prediction of poorer survival of the 
never-smoked lung cancer patients with adenocarcinoma 
is in great agreement with our experimental findings 
showing As3+ induces Akt-dependent phosphorylation of 
filamin A and cell migration.
In summary, this report presented a novel 
mechanism for the contributions of As3+ to human cancer. 
The data suggest that As3+ is capable of regulating the 
tumorigenesis through ROS dependent activation of 
protein kinase Akt that phosphorylates filamin A, leading 
to an enhanced crosslinking between actin filaments 
and integrin by filamin A and the subsequent migration 
of the cells. As cell motility or migration is one of the 
key steps for tumor cells metastasis [42], regulation on 
the binding capability of filamin A on integrin and actin 
network certainly will influence the disease progression 
of the cancer patients. Indeed, a recent study showed 
that filamin A promotes migration and invasive potential 
of breast cancer cells through interaction with cyclin 
D1 [43]. This notion was further supported by the 
observations that overexpression of filamin A is associated 
with highly metastatic cancers, such as melanoma [44], 
neuroblastoma [45], breast cancer [46], and prostate 
cancer [47]. Accordingly, the findings in this report may 
be potentially translated into new therapeutic strategies 
by targeting Akt kinase and filamin A in cancers resulting 
from exposure to As3+ or other environmental carcinogens.
MATERIALS AND METHODS
Cell lines and reagents
The human bronchial epithelial cell line BEAS-
2B, and human embryonic kidney 293 cell line HEK-293 
were obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). The BEAS-2B cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
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Invitrogen, Grand Island, NY) containing 5% fetal bovine 
serum (FBS, Invitrogen), 1% penicillin/streptomycin, and 
1% L-glutamine (Sigma, St. Louis, MO) at 37°C humidified 
incubator with 5% CO2. The human embryonic kidney 
293 cell line HEK-293 was maintained in DMEM containing 
10% FBS, 1% penicillin/streptomycin, and 1% L-glutamine 
at 37°C humidified incubator with 5% CO2. The cells 
were treated with As3+ [arsenic (III) chloride, Sigma-Aldrich, 
St. Louis, MO], with the indicated concentrations and times 
when the cells reached an approximately 80% confluence. In 
some experiments, PI3K/Akt inhibitor Wortmannin or ROS 
scavenger N-acetyl-cysteine (NAC) were added 2 h prior to 
As3+ treatment.
Plasmid preparation and transfection
Constructs of pcDNA3-myc-Flna wild type 
(WT) and pcDNA3-myc-Flna S2152A were purchased 
from Addgene (Cambridge, MA). The plasmid DNA 
was amplified in DH5α Competent cells (Invitrogen, 
Grand Island, NY) and purified using either Plasmid 
Purification Kit (QIAGEN, Valencia, CA) or HQ 
Mini Plasmid Purification Kit (Invitrogen) according 
to the manufacturer’s protocol. Cells in 6-well plates 
were transfected either with 50 ng plasmid DNA using 
Lipofectamine RNAiMAX Transfection Reagent 
(Invitrogen) or 2 μg plasmid DNA with Nucleofector 
(Lonza, Anaheim, CA) with program G016.
Western blotting
For regular Western blotting, the cell lysates 
were prepared by RIPA cell lysis buffer (Cell 
Signaling, Danvers, MA) followed by ultrasonication 
and centrifugation. The supernatants were aspirated 
and proteins were quantified using a SpectraMax 
spectrophotometer (MDA Analytical Technologies). 
LDS sample buffer (Invitrogen) and dithiothreitol were 
added before denature. The samples were separated 
on 7.5% SDS-PAGE running gel and then transferred 
to PVDF membranes. The membranes were blocked 
in 5% non-fat milk in TBST and incubated with the 
indicated primary antibodies at 4°C overnight, and then 
incubated with second antibodies at room temperature 
for 1 h and washed with TBST 3 times for 10 min 
each. The protein levels were detected using CDP-
Star Reagent (New England Biolabs, Ipswich, MA), 
SuperSignal West Pico (Thermo Fisher Scientific, 
Waltham, MA) or Immobilon Western chemiluminescent 
HRP substrate (MILLIPORE, Billerica, MA). The 
primary antibodies used in Western blotting include 
anti-phospho-Akt (Ser473) (Cell Signaling), anti-
phospho-Akt substrate RXRXXS*/T* (Cell Signaling), 
anti-phospho-Filamin A (Cell Signaling), anti-Filmain 
A (Cell Signaling),  anti-Akt (Cell Signaling), anti-myc 
tag, (Cell Signaling), anti-GAPDH (Cell Signaling), and 
anti-β-actin (Sigma).
Immunoprecipitation (IP) and proteomics
After the indicated treatments, the cells were collected 
in IP lysis buffer and fragmented through passing the cells in 
a syringe equipped with 21.5 needle for 10–15 times. About 
500 μg protein for each indicated sample was prepared 
and then incubated with the specific antibodies that were 
conjugated with agarose beads at 4°C agitation overnight. 
The immunocomplexes were pulled down by centrifugation 
at 3,000 rpm for 10 min and separated in SDS-PAGE gel 
for regular Western blotting. After extensive washes, the 
protein bands of interest on the PVDF membrane were 
retrieved with a scalpel followed by washing the membrane 
slices in double diluted water. Proteins on the membrane 
slices were digested overnight in 50 mM ammonium 
bicarbonate, 30% acetonitrile and sequencing-grade trypsin 
(Promega, Madison, WI) at 37°C. The digestion solution 
was collected and the membranes were washed 2 times 
with 70% acetonitrile (ACN) and 1% FA with sonication. 
The solutions were pooled, speed vacuumed to dryness, 
and solubilized in 2% ACN, 0.1% FA. Protein peptides 
were separated by reverse phase chromatography (Acclaim 
PepMap100C18 column, Thermo Scientific), followed by 
ionization with the Nanospray Flex Ion Source (Thermo 
Scientific), and introduced into an orbitrap Fusion mass 
spectrometer (Thermo Scientific). The obtained spectra were 
analyzed using Proteome Discoverer 1.4.0.288 (Thermo 
Scientific) which incorporates the Mascot algorithm (Matrix 
Science, Boston, MA).
siRNA transfection
Cells with a concentration of 1 × 105/ml were seeded 
into 6-well plates and reverse transfected with siRNAs 
using Lipofectamine RNAiMAX reagent (Invitrogen). 
For short term treatment, 20 μM As3+ was added at 
24 h and cultured for an additional 2 h. SiRNA that 
specifically silence filamin A was purchased from Santa 
Cruz Technology (Santa Cruz, CA); control siRNA and 
siRNA specifically silencing Akt were purchased from 
Cell Signaling (Beverly, MA).
Cell migration assay
Cell migration was determined using BD BioCoatTM 
MatrigelTM Migration Chambers (8 μm filter). BEAS-2B 
cells were seeded with a density of 1.5 × 104/well (siRNA 
transfection) or 1 × 105 /well (plasmid transfection) in 
the upper chamber. DMEM medium containing 5% FBS 
was added into the lower chambers. The chambers were 
incubated at 37°C for 4 to 6 h, followed by replacing the 
medium contain 0.5% FBS and 4 μM As3+. After 24 hrs 
incubation, the cells in the upper chambers were scrubbed 
out using cotton-tipped swab. The cells on the lower 
surface of the membrane were stained with the Diff-Quik 
Kit (Dade Behring). The migrated cells were counted 
under a microscope for 12 random fields in each group.
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Statistics
Microsoft Excel was used for statistical analyses 
of the quantitative data. The data are expressed as 
mean ± standard deviation (SD). The student’s t-tests were 
used to determine the statistical significance of differences 
between samples treated under different conditions. 
Differences were considered statistically significant when 
*p < 0.05, **p < 0.01, or ***p < 0.001.
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